menu

Bariatric Surgery CED

Coverage with Evidence Development in Bariatric Surgery

CMTP is collaborating with Johns Hopkins University in the development and implementation of a framework that will enable payers to provide reimbursement for all clinical costs (bariatric surgery and weight loss interventions) for patients enrolled in a pilot randomized controlled trial (RCT) of bariatric surgery. We are also assisting JHU in developing an approach to apply this framework to provide coverage for clinical costs for patients that will be enrolled in a national multi-center RCT. In performing this work, CMTP is engaging with payers and other key stakeholders to form a regional alliance to serve as a platform to facilitate not only the JHU trial, but also to set priorities and implement coverage with evidence development (CED) and other strategies to support comparative effectiveness research in obesity and diabetes more generally.

Tirzepatide and semaglutide are FDA-approved for long-term weight management in adults with obesity (or overweight with a weight-related health problem), so some people now have a non-surgical option, though weight often comes back if they stop. In large trials, people taking these medicines lost about 15 to 21 percent of their body weight on average, which is generally less than the loss after gastric bypass or sleeve gastrectomy. Both medicines also lower blood sugar in adults with type 2 diabetes.

For more information on this project, contact Donna Messner.

Sources